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Abstract (word count: 248 words) 
Although overall cardiovascular (CV) mortality has declined in recent years, patients with 
clinically manifest cardiovascular disease (CVD) remain at increased risk of recurrent CV 
events. To minimise the likelihood of future CV events following an acute myocardial 
infarction (MI), changes in diet and lifestyle, alongside pharmaceutical interventions, such as 
dual antiplatelet therapy, a β-blocker, an ACE inhibitor, and a statin, are recommended 
within current clinical guidelines. The use of cardiac rehabilitation (CR) programmes has 
been shown to be highly effective in reducing mortality and morbidity following MI, and a 
cost-benefit analysis suggests that increasing the uptake of CR to 65% among eligible patient 
would result in potential cost savings of over £30 million annually for the NHS. The 
involvement of a multidisciplinary team (MDT) of healthcare professionals is central to 
delivering post-MI care, with initial and/or ongoing input from cardiologists, hospital-based 
specialist pharmacists, specialist nurses, GPs, dietitians, smoking cessation specialists and 
practice-based and community pharmacists, among others. This consensus statement was 
developed based on a meeting of HCPs actively involved in delivering CV secondary 
prevention care at primary and secondary care centres across the UK. Recognising that HCP 
team configuration and availability of resources/services vary by location, the authors have 
focused on three common themes which have broad relevance in CVD secondary 
prevention, specifically: integration of care, medicines optimisation, and encouraging 
patient activation. Opportunities for MDT members to improve outcomes in post-MI 
patients are suggested and examples of best practice models which have been implemented 
successfully are described. 
Keywords 
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INTRODUCTION 
Although overall cardiovascular mortality has declined over previous decades, patients with 
clinically manifest cardiovascular diseases (CVD) remain at increased risk of recurrent 
cardiovascular (CV) events. Among patients who survive acute myocardial infarction (MI), 
20% suffer a second CV event (non-fatal MI, non-fatal stroke, or CV-related death) within 1 
year, while approximately 50% of major coronary events occur in those with a previous 
hospital discharge diagnosis of acute myocardial infarction (AMI).1 
 
The substantially increased risk of further CV events in patients experiencing an initial event 
has led to the urgent prioritisation of measures for secondary prevention in CVD. Numerous 
clinical guidelines have been developed in an effort to improve secondary prevention in 
acute coronary syndromes (ACS) and heart failure (HF).2–5 These guidelines universally 
include a requirement for changes in lifestyle, for example by promoting healthy eating, 
regular exercise and smoking cessation, alongside pharmaceutical interventions, such as 
antiplatelet drugs, β-blockers, angiotensin-converting enzyme (ACE) inhibitors and statins.2–5 
Such a multi-faceted approach to secondary prevention in CVD is known as cardiac 
rehabilitation (CR); a term which describes individualised and systematic strategies that aim 
to minimise the risk of recurrent cardiac events through a supervised, menu-based 
programme incorporating a number of components.6,7 Post-MI care requires a mix of skills 
and expertise, so a multidisciplinary team (MDT) of healthcare professionals (HCPs) delivers 
this. The MDT may comprise cardiologists, hospital-based specialist pharmacists, specialist 
nurses, GPs, dietitians, smoking cessation specialists and practice-based and community 
pharmacists, among others. In addition to planning care based on recognised biomarkers for 
future CVD risk (e.g. high BMI, hypertension and/or dyslipidaemia), the MDT should not 
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overlook lifestyle elements which are major contributors to many primary and secondary 
CVD events (e.g. smoking, diet, inadequate levels of physical activity).  
 
The benefits of CR programmes for patients and the NHS 
The use of CR programmes has been shown to be highly effective in reducing mortality and 
morbidity following MI. In a recent Cochrane meta-analysis of 63 studies, including 14,486 
participants with median follow-up of 12 months, use of CR programmes was associated 
with a relative risk of 0.74 for CV mortality (95% confidence interval [CI]: 0.64, 0.86) and 
0.82 for hospital admission (95% CI: 0.70, 0.96).8 Of the 20 included studies reporting on 
quality of life, 14 showed higher levels of health-related quality of life in one or more 
domains following exercise-based CR compared with controls. 
 
As well as improving outcomes for individual patients, evidence suggests that the effective 
delivery of CR may lead to significant cost savings that could be reinvested in rehabilitation 
and re-ablement. Indeed, one cost-benefit analysis reported that a 65% uptake for CR 
programmes would result in a reduction of 28,782 emergency cardiac readmissions in the 
following 12 months, leading to a potential cost saving of £30,646,085.6 
 
Barriers to secondary prevention in CVD: Adherence to guidelines 
Despite the overwhelming evidence in favour of the effectiveness of CR programmes for 
patients with CVD, management of patients at risk of further CV events remains 
suboptimal.7 This may be due to two overriding deficiencies: 1) gaps in current guidelines; 
and 2) discrepancies between recommendations and current practice. In terms of the first 
deficiency, a number of questions remain to be addressed in current guidelines for 
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secondary prevention in CVD, including the lack of understanding of the incidence of statin 
intolerance in the community, the impact of stopping statin therapy in elderly patients, the 
causality of the association between anxiety and CVD risk, as well as the health impact of e-
cigarettes/vaporisers/electronic nicotine systems. Other issues yet to be resolved and 
addressed by guidelines include the most effective method for optimising blood pressure 
(BP) lowering in elderly, the threshold for hypertension intervention, and an understanding 
of the most effective diet for patients with pre-metabolic syndrome. Uncertainty about 
benefits of CR, or indeed perceptions that it may involve risk for a patient may therefore 
result in clinical inertia in terms of encouraging uptake among eligible patients.  
Non-adherence to guidelines may be unintentional on the part of HCPs due to limited 
awareness of the most applicable clinical guidance. For example, within a CR programme a 
dietitian might deliver generic guidance based on the NHS Eatwell Guide, which provides 
recommendations for a healthy, balanced diet. Guidance on diet tailored more specifically 
for post-MI patients is available from NICE in CG172 (e.g. encouraging people to eat a 
Mediterranean-style diet [more bread, fruit, vegetables and fish; less meat; and replacing 
butter and cheese with products based on plant oils])2; whereas for a post-MI patient with 
type 2 diabetes, NICE guidance in NG28 should be consulted (e.g. this encourages 
consumption of high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as 
fruit, vegetables, wholegrains and pulses)9. 
HCPs involved in prescribing secondary prevention medicines may also be failing to harness 
the full potential of these drugs by using suboptimal doses as recommended within 
guidelines. For example, only 16.3% of 270 patients attending a UK post-MI clinic were 
receiving a recommended ACE inhibitor/angiotensin receptor blocker (ARB) dose.10 
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Barriers to secondary prevention in CVD: Participation in CR programmes 
Arguably, the greatest barrier to the success of CR is its underutilisation and limited 
availability.7 In Europe, it has been reported that only one place on a CR programme is 
available for every seven patients with coronary artery disease, translating into an unmet 
need of 3,449,460 places annually.11 In the UK specifically, findings from the 2018 National 
Audit of Cardiac Rehabilitation (NACR) reported that although 76% of patients complete a 
CR programme, only 60% of the programmes on offer meet four to seven of seven defined 
service quality key performance indicators (KPIs).12 Furthermore, certain patient groups 
seem to be particularly underrepresented, including women (accounting for only 29% of the 
population taking up CR), socially deprived groups (40% of people from areas of high 
deprivation start CR, compared with 54% from areas of low deprivation) and ethnic 
minorities (80.5% of patients attending CR are white British). In addition, very few patients 
with HF currently enrol on CR programmes.12 To address these gaps in delivery, the 2018 
NACR outlined a number of key recommendations, as summarised in Box 1. 
 
Box 1. Key recommendations from the NACR 2018 report for improving outcomes from CR programmes 
1. Recruit more female patients 
2. Ensure that CR programmes are better tailored to the needs of female patients 
3. Carry out a comprehensive CR assessment prior to, and on completion of, CR 
4. Offer facilitated home-based modes of CR delivery for all CVD patients, including those with HF 
5. Ensure programmes are working to certification standards and aim to secure certified status for the 
delivery of CR 
Source: BHF 201812 
CR, cardiac rehabilitation; CVD, cardiovascular disease; HF, heart failure 
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Failures in the implementation of successful CR programmes are demonstrated by the 2015 
EUROASPIRE IV study, a large cross-sectional study undertaken at 78 centres in 24 European 
countries.13 EUROASPIRE IV showed that CVD risk factor management remains suboptimal 
for many patients, with a large majority of coronary patients failing to achieve the guideline 
standards for secondary prevention. The study reported 16% of patients continued to 
smoke cigarettes, 60% undertook little or no physical activity, 38% were obese 
(BMI ≥30 kg/m2), 42.7% had elevated blood pressure, 80.5% had elevated low-density 
lipoprotein cholesterol (LDL-C) levels and 26.8% were diagnosed with diabetes. These 
findings suggest that risk factor control is inadequate despite high reported use of 
medications, and also reveal large variations in secondary prevention practice between 
centres. 
 
How can secondary prevention in CVD be improved?  
Because of the current shortcomings in secondary prevention in CVD, including a lack of 
uptake of CR programmes, the European Society for Cardiology (ESC) published a call for 
action in 2016, setting out recommendations to address the known challenges.14 These 
recommendations can be broadly grouped into the following themes: 1) Integration of care 
(including closer communication between patient and HCP, and among HCPs; 2) Medicines 
optimisation; and 3) Improved treatment adherence. 
 
At a local level, many HCPs currently work in MDTs to try to improve care of patients with 
CVD by addressing the issues identified by the ESC call for action. This consensus document 
draws on the experiences of the authors, as active MDT members, and seeks to provide a 
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holistic perspective on CV secondary prevention models of care aligned with current clinical 
guidance and evidence-based medicine. 
 
OPPORTUNITIES FOR SECONDARY PREVENTION ALONG THE POST-MI PATHWAY 
Although secondary prevention after MI has traditionally been divided into distinct phases 
including inpatient care, outpatient care and long-term intervention, in reality it should be 
considered a continuous lifelong process that follows the patient journey and allows them 
to return to a normal life.14 A typical patient-treatment pathway for ST segment elevation 
myocardial infarction (STEMI) is shown in Figure 1, with a seamless transition from one 
stage to the next being essential. 
 
Figure 1. Management of post-STEMI patient: follow-up after PCI 
 
AF, atrial fibrillation; BP, blood pressure; DVLA, Driver and Vehicle Licensing Agency; ECG, electrocardiography; 
PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction 
Figure adapted from Dalal et al, 201715 
 
Whereas managing the primary event is the first concern of emergency physicians, it is clear 
that secondary prevention should begin immediately following the MI. In the UK, nearly 90% 
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of patients who present with acute STEMI are treated with a primary angioplasty within 90 
minutes of arrival at hospital.15 Immediate pharmacological treatment consisting of dual 
antiplatelet therapy (aspirin plus a second antiplatelet agent), a β-blocker, ACE inhibitor and 
statin therapy should then be prescribed.2 Patients are usually discharged 3 days after 
treatment for a STEMI with an uncomplicated primary PCI and are transferred to a wider 
primary healthcare team.15 It is at this stage that CR has traditionally been offered to 
patients, sometimes as a ‘nice-to-have’ in addition to their pharmacological treatments. 
However, as the importance of CR programmes becomes increasingly clear, and as uptake of 
these programmes continues to stall, it becomes essential that they are presented as a vital 
part of an overall integrated rehabilitation programme. After an intervention, such as a PCI, 
the patient should understand that they are now beginning a long-term process of recovery 
and change focused on improving their future health and reducing their risk of a secondary 
event. Some patients may interpret the success of a procedure as being “curative”, rather 
than understanding the longer-term implications of their MI and their ongoing 
cardiovascular risk. 
As identified in the ESC’s call for action, integration of care, including closer communication 
between patient and HCP and among HCPs, is essential for patient-centred CV secondary 
prevention, at all stages of the treatment pathway.14 This cooperation should begin before 
the patient is discharged from hospital, to ensure that care is continued and maintained in 
the community. The British Heart Foundation (BHF) has funded and tested nine models of 
integrated care to tackle CVD in the UK.16 Implementing integrated care using these models 
led to:  
• Improved patient access to care and quality of life 
• Provision of care outside of hospitals and closer to home 
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• HCPs working across organisational boundaries to better support the needs of 
patients and their families 
• A more cohesive care journey, reduced hospital admissions and the generation of 
cost savings and productivity gains 
  
Although variations exist in terms of local healthcare resources and team configuration, 
delivery of post-MI care by an MDT provides numerous opportunities for each HCP involved 
to support patients with the aim of improving future health outcomes (Table 1 provides 
examples). The roles and skills of the different MDT members involved often overlap, so 
areas which can and should be delivered by all team members are shown first (and in red).   
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Table 1. Opportunities for MDT members to improve post-MI CR outcomes (as roles often 
overlap, examples of areas relevant to all MDT members are also included [shown in red]) 
MDT member(s)  Steps that can be taken to improve patient outcomes (these steps are usually not 
exclusive to a single type of MDT member, those in red can be performed by 
anyone in the MDT) 
ALL members Make every contact count 
• Address patient misconceptions about health and develop the patient’s  
self-efficacy (e.g. enhance understanding that their condition is chronic and 
not “cured” at discharge) 
• Act as “CR champions” to raise patient confidence in the pathway and other 
HCPs; emphasise that other MDT members and services share same goal 
• Support CR delivery and encourage participation in CR 
• Support long-term follow-up of patient by monitoring and minimising CV  
risk factors  
• Assess attitudes to lifestyle change; deliver and reinforce CR messages to 
educate patient on diet, lifestyle and smoking  
• Assess attitudes to medication, medicines tolerance and adherence, and 
medication taking behaviour 
Cardiologist • Reinforce value of lifestyle changes and reducing CV risk factors 
• Provide specialist expertise to support medication reviews 
• Adopt technology solutions (e.g., offering video consultations) to increase 
capacity and accessibility of cardiology clinics as part of follow-up) 
Hospital-based CV 
specialist 
pharmacist 
• Support patients with co-morbidities and medication issues, e.g. pain 
management (if medicines were stopped during hospital stay), managing 
diabetes medicines, and other medicines optimisation issues in the complex 
post-MI patients who are often have co-morbidities 
• Act as “Medicines experts”, supporting others in the MDT team with 
medicines-related issues  
• Reconcile medicines and identify adherence issues at admission 
• Initiate and titrate secondary prevention medications during hospital stay and 
outpatient clinics where applicable 
• Ensure discharge summary is detailed/complete and available to MDT 
members in primary care – use ‘Electronic transfer of care’ where available 
• Educate patients on CVD risk factors and how medicines help optimise these 
• Refer patients to community/GP practice-based pharmacy for NMS and SMR 
(supporting appropriate titration, and adherence over time) 
GP • Use relationship to address patient concerns about CR/medication, risk of 
future CV events 
• Identify and manage co-morbidities in CVD patients, e.g. HF 
• Arrange referrals to specialist care/local support, e.g. for smoking cessation 
• Organise annual reviews and follow-up 
Nurse CR/CVD 
specialist 
• Explain the meaning of blood tests and other test results 
• Act as HCP prescribers within CR team to help achieve targets for CVD risk 
factor control 
• Apply behaviour change models to the care delivered and use effective 
communication skills, e.g. motivational interviewing, to support patient 
engagement and motivation 
• Support delivery of comprehensive, individualised and menu-driven CR 
programmes that meet BACPR standards, including smoking cessation as a 
priority 
• Ensure timely referrals to other HCPs and service providers, e.g. smoking 
cessation 
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• Support seamless transition to long-term management 
Community or 
practice-based 
pharmacist  
• Reinforce consistent CR programme messages about healthy lifestyle, CVD risk 
reduction 
• Provide easy to access support (e.g. there are 1.6 million visits per day to UK 
community pharmacies; many are open at evenings and/or weekends) 
• Assist in detection of CVD (through NHS Health checks, BP and HbA1c checks 
and AF case-finding using new technologies) and in management by 
supporting healthy lifestyles (diet, exercise, smoking cessation, weight 
management programmes, signposting to local support) 
• Act as pharmacist prescribers managing long-term conditions and through 
disease monitoring (blood pressure, HbA1c, INR) and through offering 
adherence support through the NMS/SMR 
• Practice-based pharmacists can support patient audits, CVD case-finding 
• Support and encourage patients to attend CR 
Registered 
dietitian (RD) 
• See patients at key (or ideally, at all) phases of CR to ensure adherence to 
dietary changes 
• Support and sustain behaviour change 
• Help support physical activity and improvements in strength through 
combined exercise and nutrition (especially as change in strength is a 
powerful predictor of mortality post-MI) 
• Identify and prevent malnutrition 
• Potential to assist with monitoring medications (if qualified as a 
supplementary prescriber) 
Physiotherapist/ 
exercise specialist 
• Develop individualised exercise plan and goals, e.g. taking account of 
comorbidities such as arthritis, stroke and respiratory problems 
• Support return to work and self-management of the condition 
• Potential to assist with monitoring medications (if qualified as a 
supplementary prescriber) 
AF, atrial fibrillation; BP, blood pressure; CR, cardiac rehabilitation; CV, cardiovascular; CVD, cardiovascular 
disease; GP, General practitioner; HF, heart failure; HbA1c, glycosylated haemoglobin; INR, International 
Normalised Ratio; SMR, Structured Medication Review; NMS, New Medicine Service 
*The examples in the table are not exhaustive lists – the MDT skillset and pathway can vary in different 
regions, so HCPs may take on more or less activity in support of their post-MI pathway locally. 
 
Over the medium- and long-term follow-up, the need for medicines optimisation becomes 
increasingly important. Guidelines recommend ongoing monitoring and titration of 
medications for secondary prevention in CVD, as well as the need to review continuing the 
antiplatelet and β-blocker therapy beyond 1 year.2 However, there is considerable evidence 
to show that opportunities are frequently missed by not prescribing secondary prevention 
medicines at optimal doses.10 For example, one UK-based study found that more than 25% 
of patients with pre-existing coronary heart disease who were readmitted with an ACS were 
receiving a suboptimal secondary prevention drug regimen at time of admission, with many 
of those patients failing to achieve cholesterol and blood pressure targets.17 A medicines 
 14 
optimisation and patient adherence strategy based on a cooperation between HCPs can 
improve both adherence and outcomes post-MI.10 
 
Similarly, adherence to medication regimens is essential during medium- and long-term 
follow-up after MI.18 Non-adherence to statins in the 12 months following an MI is 
associated with a 12% to 25% increased hazard for mortality19, while 1-year survival reduces 
from 98% to 89% within the first year after MI in patients discontinuing aspirin, statin and β-
blockers20. Despite the evidence for the importance of adherence to medication following 
an MI, data suggests that medication adherence is highly variable and often suboptimal.18,21 
Within a recent UK postal survey of patients with CAD treated at a secondary/tertiary care 
centre, 43.5% of patients were found to be non-adherent for at least one of their secondary 
prevention medicines. In the non-adherent patients, 30.8% reported this was at least partly 
intentional. Overall, forgetfulness, concerns about the medicines doing more harm than 
good, and feeling hassled about medicines, were the main barriers reported by patients. 
These findings show that HCPs should explore their patients’ beliefs and experiences with 
their medicines and tailor adherence interventions individually to overcome such barriers.21 
 
 
PRIORITIES AT EACH STEP OF THE PATHWAY 
At each step of the patient-treatment pathway, priorities may change once the immediate 
aftermath of the MI is addressed and a more long-term focus becomes more important. At 
admission, the immediate priority is for reperfusion, confirmation of diagnosis and 
stabilisation of the patient.22 Once these have been achieved, other priorities become more 
relevant. Key priorities in the early stages following an event are to address cardiovascular 
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risk factors, modify unhealthy lifestyle and diet issues, avoid future events and optimise 
patient engagement. In practical terms, this may mean the following interventions will be 
required. 
 
1. Encouraging smoking cessation 
For CVD patients who smoke, quitting is an urgent priority and all members of the MDT 
(including hospital- and GP clinic-/community-based HCPs) should actively support this goal. 
Results of a 2003 systematic review indicated that quitting smoking after AMI or cardiac 
surgery can decrease the risk of death by at least one third23, while the risk of AMI has been 
shown to be significantly reduced within a few years of quitting24. Cessation also 
significantly reduces the risk of recurrent cardiac arrest.25 The NHS Long Term Plan for 
2019/20 to 2023/4 includes plans to offer support to stop smoking to all smokers who are 
admitted to hospital, and the government has recently set out its ambition for the UK to 
eliminate smoking by 2030 in a green paper focusing on disease prevention.26 
 
In contrast to other areas of clinical care for post-MI patients such as managing type 2 
diabetes, where there is a clear pathway for referrals and collaborative working with other 
HCPs, for smoking cessation, HCPs may limit their input to signposting their patient to a local 
support group without further follow-up. Smokers are up to four times more likely to quit 
successfully if they use a combination of stop smoking medicine and specialist help and 
support from the NHS.27 MDT members can help patients to achieve this by booking an 
appointment with a local behavioural support group, providing very brief advice, or actively 
prescribing one of the approved evidence-based cessation pharmacotherapies (bupropion, 
varenicline or nicotine replacement therapy [NRT]).28 A large randomised placebo- and 
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active-controlled clinical study, Evaluating Adverse Events in a Global Smoking Cessation 
Study [EAGLES], has demonstrated that these pharmacotherapies (bupropion, varenicline 
and NRT) do not increase the risk of serious CV events in the general population of 
smokers.29 Separate analysis from the EAGLES trial found there was no significant increase 
in neuropsychiatric adverse events attributable to varenicline or bupropion relative to 
nicotine patch or placebo. Varenicline was more effective than placebo, nicotine patch, and 
bupropion in helping smokers achieve abstinence, whereas bupropion and nicotine patch 
were more effective than placebo.30 Overall, these data provide reassurance that these 
therapies provide safe and effective options to increase a patient’s likelihood of success in 
quitting. 
 
Patients who are not ready to quit should still be provided with encouragement to do so and 
given an understanding of the health benefits they may expect from this. If patients have 
concerns about quitting, for example if they view nicotine intake as a coping mechanism for 
stress, or that they may gain weight, these should be addressed and appropriate support 
strategies offered, e.g. dietary advice, behavioural support on stress management, advice 
on how to optimise use of different NRT patches to provide background nicotine versus use 
of NRT gum/lozenges/mist products to provide rapid relief of cravings. 
 
The National Centre for Smoking Cessation and Training (NCSCT) provides a training module 
on very brief advice for HCPs to offer patients (https://www.ncsct.co.uk/publication_very-
brief-advice.php) and other resources to support the delivery of smoking cessation 
interventions by the NHS and Local Authorities. Even brief and simple advice given by a 
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physician can increase unassisted quit rate by 1–3%31, so referral to a dedicated programme 
can have a significant impact on smoking rates.  
 
2. Promoting participation in a tailored CR programme 
The NHS Long Term Plan recognises that uptake of CR across England is currently suboptimal 
(only 62,822 or 52% of the 121,500 eligible patients per year take up offers of CR.32 Under 
this plan, scaling up and improving marketing of CR to be amongst the best in Europe aims 
to ensure that 85% of eligible patients access CR, which will prevent up to 23,000 premature 
deaths and 50,000 acute admissions over 10 years. 
 
CR programmes used to be viewed by some HCPs as a bolt-on to prescribed drug regimens. 
However, they are now very much recognised as being part of an integrated care package, 
including lifestyle modifications and pharmacological treatments. Examples of different CR 
programmes are described in the section below, and interventions such as these should be 
offered to patients as part of an overall treatment strategy. Rather than providing a 
traditional/‘one-size-fits-all’ programme, the format should offer an individualised, menu-
based approach, tailored to the patient’s preferences and abilities, for example working-age 
patients may prefer online/home-based follow-up over attendance at group-based CR 
sessions, uptake may be enhanced in some communities by offering translated versions of 
materials and/or interpreter support. Digital options such as app-based and web-based 
online platforms for remote monitoring could also help in increasing uptake. For example, 
Activate Your Heart is an interactive web-based CR service currently being trialled in 250 
patients in Scotland – the programme offers 24/7 access to classes through patients’ 
computers or mobile devices, cutting out the need to travel to appointments at fixed times 
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and locations.33 The appeal of these options is not restricted to working age patients – they 
could be convenient for those living in rural areas and preferred if anyone does not like 
group-based activities.  
 
An opportunity to engage with CR may be missed if there is inadequate handover to the 
primary care team when a patient is discharged from the hospital. If the patient leaves 
without fully understanding the scope of the support available, they may revert to old 
habits, and visit a GP infrequently. It is therefore essential that patients be introduced to a 
CR programme prior to leaving hospital, and that they be rapidly followed up on returning 
home. Following an MI, a patient may be receptive to the message that although their CV 
event has been managed, their future risk for CVD is significantly elevated and therefore 
steps to manage this risk need to start now and continue in the future. The information 
conveyed should be kept as concise and clear as possible to avoid overloading the patient 
who is still in the early phase of recovery from a traumatic experience. 
 
It is also important that the patient continues to receive ongoing care and contact from the 
CR support team throughout their recovery. It is very easy for patients to fall back into old 
habits during recovery, particularly when they start to feel better, and there must be 
ongoing interventions to ensure that the lifestyle changes continue to be adopted. 
 
3. Arranging follow-up cardiac imaging 
After MI, optimal clinical management depends critically on cardiac imaging. In the acute (0 
to 48 hours post-event) and subacute (3 to 7 days post-event), cardiac imaging is performed 
using echocardiography.34 This imaging assesses segmental and overall ventricular systolic 
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function, intracavity thrombus formation, and other mechanical complications of MI. An 
echo is recommended within 24–48 hours of MI and an additional echo is recommended 
within the first 3 months after infarction to provide a post-infarction baseline assessment of 
function.34 HF is a major cause of late morbidity and mortality after MI, however cardiac 
imaging and other approaches for early identification of patients at risk of HF are currently 
poorly integrated.35  
 
For patients who have had an acute MI and who have symptoms and/or signs of heart 
failure and left ventricular systolic dysfunction, NICE recommends initiating treatment with 
an aldosterone antagonist licensed for post-MI treatment within 3–14 days of the MI, 
preferably after ACE inhibitor therapy.2 However, a recent UK study found that prior to a 
medicines optimisation review, only 60.5% of post-MI patients who were suitable for 
eplerenone had been initiated on this medicine.10  
 
4. Promoting healthy lifestyle behaviours 
Nutrition and lifestyle have a central role in both the primary and secondary prevention of 
CVD, and is reflected in national2,36 and international guidelines.4,37 The primary reason for 
this is that so many of the established risk factors for CVD such as dyslipidaemia, 
hypertension, obesity, and type 2 diabetes are all heavily influenced by diet.38 Current NACR 
data show the relatively poor impact that CR currently has on reducing body mass index 
(BMI), and the relatively small gains that are seen in the number of patients achieving total 
and LDL cholesterol, and hypertension targets.12 These beneficial changes are likely 
primarily due to the intensive pharmacotherapy that these patients are prescribed post 
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cardiac event, and that such changes in BMI, lipids, and BP may be even greater if lifestyle is 
adequately addressed.  
 
Modest weight loss of 5–10% can have a substantial impact on both physical and metabolic 
consequences of obesity39, however it is ideal that weight loss is excess fat tissue, and not 
muscle. Recent data has shown that BMI is a weak predictor of major adverse 
cardiovascular events (MACE) in post-MI patients, and body fat and fat free mass are 
superior.40 Therefore, whilst BMI is an easy measure to perform, additional measures that 
accurately look at body composition may aid in weight management during CR. It is 
important to note that weight management can also mean supporting patients to maintain 
or gain weight if needed. In a study of 174 elderly patients admitted for acute MI, a greater 
degree of malnutrition was associated with a significantly increased risk of all-cause 
mortality.41 The implications for CR are substantial, and AMI patients who are underweight 
on admission should be seen by a dietitian prior to discharge. 
 
There is an ongoing debate regarding the best diets for weight loss (low carbohydrate or low 
calorie). This was addressed by DIETFITS showing that similar calorie reductions from either 
a low fat or low carbohydrate lead to weight loss and similar improvements in blood 
pressure, fasting insulin, and fasting glucose.42 Manipulating the nutrient composition can 
provide added benefit in improving CV risk factors such as BP, glucose, and lipids. The large 
PREDIMED multicentre trial in Spain randomised 7,447 individuals who were at high CV risk 
to a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet 
supplemented with mixed nuts, or a control diet (advice to reduce dietary fat).43 The 
incidence of major CV events was lower among those assigned to a Mediterranean diet 
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supplemented with extra-virgin olive oil or nuts than among those assigned to a reduced-fat 
diet, demonstrating that diets differ in their extent of cardioprotection. Studies such as 
these reinforce that it is not sufficient to deliver generic healthy eating advice in CR, other 
than as a foundation to build on. Patients require careful education around dietary fats, 
sources, and also nomenclature (saturated, unsaturated, and types of fat such as 
hydrogenated vegetable oil). This education can also help to empower patients to 
understand food labels and give them confidence to make cardioprotective food choices, in 
line with JBS3 recommendations to “avoid/reduce consumption of calorie rich but 
nutritionally poor snacks”.44 Any HCP working in this area should have a broad 
understanding of nutrition and be able to refer on to dietitians for more complicated issues. 
 
Advice regarding how to implement any changes to diet must be carefully tailored to each 
individual patient, accounting for differences in taste, cooking skills and facilities, 
educational level, and their understanding of the importance of good nutrition. As CVD is 
more common in individuals with lower educational attainment and socioeconomic status45, 
care must be taken not to make lifestyle changes impossible to follow. Knowing patients’ 
circumstances outside of the CR location can make a substantial impact on the quality of 
nutritional advice provided. Familiarity with affordable alternatives is essential, e.g. 
considering tinned sardines or mackerel as an alternative to fresh salmon. 
 
5. Regular medication review and medicines optimisation 
As discussed previously, ongoing monitoring and titration of medications for secondary 
prevention in CVD, as well as the need to review continuing the antiplatelet and β-blocker 
therapy beyond 1 year are recommended in current clinical guidance.2  Regular review of 
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the patient’s medication needs allows their regimen to be adjusted as appropriate e.g. to 
uptitrate medicines optimise efficacy and to meet targets for cholesterol levels, blood 
pressure and HbA1c. It may also be appropriate to reduce or replace medications if a 
patient’s needs have changed, for example if their level of liver or renal function has 
changed over time affecting clearance of medicines they are taking. In line with NICE 
guidance adherence should also be assessed and any patient concerns about their 
medication addressed.46 
In a recent prospective, controlled feasibility/pilot study in London, the impact of a 
pharmacy care intervention on adherence to medication and on health outcomes was 
explored in patients with ACS.47 Community pharmacists delivered an intervention involving 
a 15 to 20-minute motivational interview to the patients, either face-to-face or by 
telephone. After 6 months, self-reported medication adherence among those receiving 
motivational support from community pharmacist was 17% greater than that recorded in 
control patients. As improved adherence to secondary prevention medication for coronary 
heart disease would promote better clinical outcomes, the study demonstrates the 
feasibility and value of interventions by pharmacists and other MDT members to support 
adherence. In the following section covering models of best practice, further examples of 
medicines review, and medicines optimisation are discussed.  
 
EXAMPLES OF BEST PRACTICE AND FUTURE TRENDS 
This section discusses examples of current best practice and trends regarding optimisation 
of care in CVD across a variety of models and locations in the UK. These models are based 
on the experience of the authors and provide examples that may be applicable to other 
regions in the UK. 
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Hospital-based post-MI medicines optimisation: A joint consultant pharmacist and 
cardiologist clinic model 
Post-MI patients at Leeds Teaching Hospitals NHS Trust are offered the opportunity to join 
the Leeds Medicines Optimisation Clinic Project.10 In this model, patients typically have a 
short stay in hospital (around 2.5 days), then are seen by the CR team in hospital 
immediately before discharge to receive initial advice and for a handover to the CR team in 
the community. After discharge, patients return to the hospital to attend this clinic, and are 
then followed up by community-based nurses for CR care. The process is illustrated in Figure 
2. 
 
Figure 2. The Leeds Universities post-MI medicines optimisation programme 
 
GP, general practitioner; MI, myocardial infarction 
 
All team members adopt a person-centred approach in the clinic and innovative new tools 
such as the MYMEDS questionnaire are used to explore for modifiable barriers to 
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adherence. Where needed, patients can also be referred to statin-intolerance and PCSK9i 
clinics as part of the pathway. The improved optimisation of therapy has demonstrated 
improvement in adherence and better outcomes post-MI.10 
 
The Leeds post-MI pathway is a 12-month process rather than the more typical 3-month 
programme and culminates in a virtual 12-month review performed by the specialist with 
access to key details (current medicines, test results, ongoing concerns) to assess CV risk 
factors and medicines optimisation. This review provides a recommendation back to the 
patient’s GP or practice-based pharmacist regarding whether the criteria to continue 
antiplatelet therapy are met, and the final decision is made in consultation with the patient. 
 
The integration between primary and secondary cardiac care offered by this model assists 
GPs who may lack confidence or require additional support when making treatment 
decisions. Indeed, although GPs in Leeds can make the decision to continue antiplatelet 
therapy if they feel confident to do so, there is a specialised review service available if GPs 
have any concerns or if the case is particularly complex. The antiplatelet review service is a 
virtual review service carried out by the hospital pharmacy team, an interventionalist and a 
general cardiologist. This close working arrangement also offers support to pharmacists in 
primary care who may be concerned about having to make a decision regarding 
continuation of antiplatelet therapy at 12 months. Patients also feel more reassured by 
dealing with HCPs (e.g. a pharmacist) if they are presented as part of a CR team, working in 
partnership with their cardiologist, particularly when they show knowledge of what the 
patient has been through and are not just focused on a particular issue (e.g. recapping the 
patient’s medical history in the first meeting). Pharmacists benefit too, with research 
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showing that practice-based pharmacists involved in this process feel much more integrated 
within the team compared with community-based pharmacists who may feel outside the 
system. 
 
To enhance this model further, work is currently ongoing on an IT system to flag suboptimal 
medicines and/or CV risk factor management, to allow the patient to be referred back to 
their GP to address issues identified in the 12-month review.  
The Leeds medicines optimisation model can be used in secondary or primary care-based 
pharmacy teams. As only 42% of 302 audited CR schemes currently have pharmacist 
involvement12, there is a great opportunity to increase their role in this way, particularly as 
many pharmacists become qualified as prescribers. 
 
Integrated community-based CVD prevention: MyAction nurse-led programme 
MyAction is an integrated community-based nurse-led CV prevention programme. In this 
model, an MDT consisting of CV nurses, dieticians, physical activity specialists, and 
administrative staff supported centrally by a lead nurse, clinical psychologist and consultant 
cardiologist offer support to patients with established CVD or who are at high multifactorial 
risk for CVD over a 12-week period.48 As well as a standard clinical assessment, the initial 
patient review includes patient-reported outcome measures, defining patient priorities in 
terms of reducing their CV risk, as well as an exploration of patient beliefs, barriers and 
motivators to change. The 12-week programme includes an individualised follow-up and a 
weekly educational workshop and supervised exercise session. CV risk factor management is 
assessed at a weekly meeting held between the MDT and cardiologist, and therapeutic 
decisions are communicated to the primary care practitioner. After programme completion, 
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the patients undergo an end-of-programme assessment, with a further assessment at 1 
year. 
 
The results of this programme are striking, with significant reductions found in levels of 
smoking, as well as significant increases in the proportions of patients achieving fitness, 
blood pressure and LDL-C targets. Adherence to statins and antihypertensive medications is 
also substantially increased, while significant improvements in depression scores and 
quality-of-life measures have been seen. The majority of improvements are maintained at 1-
year follow-up.48 
 
Improving diagnosis and management of HF: A one-stop specialist GP clinic model 
In the UK, 580,000 people are on their GP’s HF register.49 However as many as 920,000 
people are living with HF when hospital diagnoses are included50, suggesting that there are 
barriers to accurate diagnosis of chronic HF within primary care. A one-stop diagnostic clinic 
model for HF that has been used in the NHS Darlington Clinical Commissioning Group since 
2002 has proven to be highly effective51, achieving a higher percentage of patients with HF 
due to left ventricular systolic dysfunction who are treated with ACE-inhibitors/ARBs and β-
blockers than demographically similar CCGs.52 This model integrates GP specialist, HF nurse 
input in primary care with a cardiologist’s hospital-based clinic. Patients are referred to CR 
where appropriate. 
In a qualitative study in 2003, reasons why GPs had not implemented best evidence in the 
diagnosis and management of HF were identified.53 At that time, key barriers included a lack 
of confidence in diagnosis and management, a lack of awareness of the relevant evidence 
base for care, and variation in GPs’ personal preferences and organisational care pathways. 
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Ten years later, a national survey found that reported differences in the way HF is diagnosed 
and managed had changed little in the past decade.54 The finding that only 54.7% of the 
respondents (made up of GPs, n=251; cardiologists, n=103; general physicians n=54; and HF 
nurses, n=78) had access to rehabilitation for their HF patients suggests that greater access 
to CR programmes is needed. 
 
Offering CR format options: Home-based programmes 
As the requirement to attend regular sessions at a hospital or other venue for group-based 
CR programmes may act as a barrier to participation, home-based schemes may offer a 
viable and more accessible alternative. NHS Lothian is responsible for the Heart Manual, a 
home-based CR programme facilitated by HCPs which has been used across the UK to 
support individuals recovering from MI and revascularisation. This programme was first 
reported in 1992 and was demonstrated to be as effective as a hospital-based regimen in 
improving CV health following an AMI.55 In a recent update on this programme, patients 
reported that having a comprehensive programme, which combined several themes, was 
the most beneficial aid to their recovery.56 The themes included (ranked from greatest to 
the least impact) were health behaviour change and modifiable risk factor reduction, 
psychosocial support, education, support, vocational rehabilitation, medical risk 
management and long-term strategies. Patients found that the programme has a profound 
impact on their daily lives and proved advantageous for CR.  
 
For patients with HF, a home-based CR intervention facilitated by an HCP is also available.57 
The Rehabilitation EnAblement in CHronic Heart Failure (REACH-HF) intervention has been 
 28 
shown to be clinically superior in disease-specific health-related quality of life at 12 months 
and offers an affordable alternative to traditional centre-based programmes.57 
 
Enhancing GP care for CVD: The role of Primary Care Networks 
The introduction of Primary Care Networks (PCNs) underway across England is expected to 
provide opportunities to improve post-MI care and help in detecting undiagnosed risk 
factors.58 Although PCNs are not yet promoting CR, they will eventually be required to 
deliver a set of seven national service specifications, including areas of relevance to CVD. 
Five of the standards will start by April 2020: SMRs, enhanced health in care homes, 
anticipatory care (with community services), personalised care and supporting early cancer 
diagnosis. The remaining two will start by 2021: CVD case-finding and locally agreed action 
to tackle inequalities.58 
 
PCNs are highlighted in the recently published 5-year framework for the GP contract reform 
as “an essential building block of every Integrated Care System”59 and, over time, patients 
should benefit from improved access to specialist HCP expertise and facilities through 
pooling of resources and staff among GPs practices within PCNs. 
 
Community and Practice-based Pharmacy: Supporting medication adherence and CVD risk 
factor management 
The New Medicines Service (NMS) provides support for people with long-term conditions 
newly prescribed a medicine in order to try to improve treatment adherence. The scheme is 
provided by more than 90% of community pharmacies.60 Patients on multiple medicines, 
particularly those receiving medicines for long-term conditions may also benefit from 
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Structured Medication Reviews (SMRs) (under the NHS Long Term Plan for 2019/20 to 
2023/4, SMRs carried out by pharmacists working within PCNs as part of the new GP 
contract arrangements will be phased in to replace the Medicines Use Review (MUR) 
services provided by pharmacists).61 The SMR is a critical examination of a person's 
medicines with the objective of reaching an agreement with the person about treatment, 
optimising the impact of medicines, minimising the number of medication‑related problems 
and reducing waste. 
 
Information from the pharmacist-led SMR should be provided to the patient’s GP where 
there is an issue for them to consider. The frequency of medication reviews should be based 
on the health and care needs of the person. Safety should be the most important factor 
when deciding how often to do the review and the frequency should be recorded in the 
patient’s care plan. 
 
Practice-based and community pharmacies can also support post-MI patients with self-
management of CVD risk factors, e.g. by providing advice on smoking cessation or weight 
control, and can also help identify patients with elevated CVD risk, e.g. through screening 
programmes, such as the NHS HealthCheck, or point of care testing for QRISK® score. 
 
Encouraging patient engagement in deprived areas: Partnering with community 
organisations 
The UK’s life expectancy is below that of many comparator countries, especially for women, 
for whom there has been no improvement since 2011. Inequalities are widening, and the 
UK’s healthcare expenditure and resources are below those of comparator countries.62 
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Deprivation adversely affects patient engagement in healthcare, as exemplified by the fact 
that uptake of the NHS Health Check is higher in more affluent areas. This is particularly the 
case where English may not be the first language spoken in all families. It is essential, 
therefore, to ensure that patients living in less affluent areas have the same access to 
support services in secondary CV prevention as their wealthier neighbours in other districts. 
Attempts have been made to achieve this goal in East London, where a community-based 
atrial fibrillation (AF) screening service has been established.63 In this project, a specialist 
anticoagulation pharmacist who is able to speak Hindi, Punjabi and Urdu held screening 
sessions in a South Asian community organisation and a Sikh temple. The programme was 
successful in detecting high-risk individuals, who do not frequently access healthcare, and 
provided screening within the familiar surroundings of local community organisations. The 
team behind the AF screening project is working with the local Council for Voluntary 
Services in order to establish an integrated care pathway. 
 
Harnessing technology: Cardiologist consultations via video 
Travel to hospital to visit a consultant can be one barrier to patient access, as it requires 
time off work in some cases, or a difficult and uncomfortable journey in cases of more 
severely ill patients. In February 2019, Lewisham and Greenwich NHS Trust became the first 
NHS Trust in England to offer video consultations for cardiology patients, to allow access 
specialist advice without requirement for travel.64 The consultations allow cardiologists to 
offer important expert advice and arrange further tests where necessary without the need 
for patients to return to the hospital, having already been seen in the emergency 
department. It will be interesting to observe whether implementation of this approach and 
other technology-based solutions enable greater capacity in cardiology clinics and reduce 
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the numbers of missed appointments, while increasing convenience for both HCPs and 
patients alike.   
 
SUMMARY  
Secondary prevention in CVD offer significant benefits to patients in terms of reduced 
mortality, reduced morbidity and improved quality of life. However, due to shortcomings in 
the delivery of secondary prevention programmes, outcomes for patients with CVD are 
currently suboptimal in the UK. This consensus statement offers practical examples of the 
interventions that are required to deliver effective CR across all stages of the patient-
treatment pathway following a cardiac event. In addition, a range of best practice models 
from across the UK that are currently achieving success in reducing CV risk are described 
and endorsed with a view to being adopted or adapted elsewhere. These include a 
pharmacist-led, hospital-based post-MI medicines optimisation programme, a nurse-led 
integrated community-based CVD prevention programme, and a GP-led one stop HF 
diagnosis and management clinic model for primary care. These models illustrate ways in 
which different HCPs involved in providing MDT care can work together to improve patient 
outcomes in CVD (Ilustrated in Figure 3). 
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Figure 3. Harnessing the skills and expertise of MDT through CR in patient-focused CVD 
secondary prevention 
 
MDT members are central to delivering CV secondary prevention care. Across the UK, they 
often work with local variations in team configuration and resource/services availability. The 
authors of this consensus statement wish to encourage greater integration of care through 
closer working between MDT members both within primary care, and between colleagues 
working in different settings. For example, cardiologists and specialist pharmacists in 
secondary care can offer valuable advice and support for primary care colleagues and vice 
versa. Individually, MDT members can identify and optimise opportunities for secondary CV 
prevention in their daily practice. Regardless of the MDT member’s role or location, each 
HCP can actively work to optimise their patient care pathway and to reinforce patient 
activation. After a CV event, a patient must embark on a lifelong journey of change designed 
to minimise the risk of secondary events. Without ongoing support and understanding from 
their HCP, these changes may appear more daunting. For example, attempting smoking 
cessation without support is substantially less likely to succeed than an attempt with HCP 
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support. Similarly, promoting engagement with CR, ensuring the patient recognises the 
importance of adherence to medication, is encouraged to adopt healthy lifestyle behaviour, 
and understands the rationale for attending specialist follow-up appointments, for example 
for imaging, are opportunities for HCPs to reinforce the changes needed for the patient to 
minimise their future CVD risk.  
Embracing the challenge of sub-optimal outcomes in CVD will also require HCPs to leverage 
potential benefits of changes in the NHS, for example the roll-out of PCNs, and to harness 
technology solutions which can provide greater flexibility for patients to engage in their 
healthcare, for example video consultations or home-based CR programmes. It is hoped that 
by focusing on integration of care, medicines optimisation and encouraging patient 
activation, the immediate and long-term outcomes can be improved for our patients 
following a CVD event. 
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